W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Transparency Council

16 August, 2022

Opinion of the Transparency Council – health policy programme on thyroid diseases (Town of Leszno)

16 August, 2022

Opinion of the Transparency Council – health policy programme on infertility treatment (Rzeszów)

16 August, 2022

Opinion of the Transparency Council – health policy programme on breast cancer (Municipality of Toszek)

16 August, 2022

Position of the Transparency Council – Inovelon (rufinamide)

16 August, 2022

Position of the Transparency Council – Fycompa (perampanel)

16 August, 2022

Opinion of the Transparency Council – changes to the drug programme B.82

16 August, 2022

Opinion of the Transparency Council – active substance etanercept

16 August, 2022

Opinion of the Transparency Council – changes to the drug programme B.44

16 August, 2022

Position of the Transparency Council – Ozurdex (dexamethasone)

12 August, 2022

Position of the Transparency Council – Tremfya (guselkumab)

12 August, 2022

Position of the Transparency Council – Suliqua (insulinum glarginum + lixisenatidum)

12 August, 2022

Position of the Transparency Council – Onureg (azacitidine)

05 August, 2022

The Meeting of the Transparency Council No. 32/2022 of 16.08.2022

04 August, 2022

The Meeting of the Transparency Council No. 31/2022 of 11.08.2022

28 July, 2022

The Meeting of the Transparency Council No. 30/2022 of 01.08.2022.

26 July, 2022

Opinion of the Transparency Council – health policy programme on therapeutic rehabilitation (town of Żyrardów)

26 July, 2022

Opinion of the Transparency Council – health policy programme on breast cancer prevention (town of Sieradz)

26 July, 2022

Opinion of the Transparency Council – changes to the drug programme B.61

26 July, 2022

Opinion of the Transparency Council – active substance ipratropii bromidum

26 July, 2022

Opinion of the Transparency Council – active substances fenoteroli hydrobromidum + ipratropii bromidum

26 July, 2022

Opinion of the Transparency Council – active substance prednisone

26 July, 2022

Opinion of the Transparency Council – active substances amiloridum + hydrochlorothiazidum

26 July, 2022

Opinion of the Transparency Council – health policy programme on medical rehabilitation (Municipality of Mielno)

26 July, 2022

Opinion of the Transparency Council – health policy programme on detection of vision defects (Municipality of Chociwel)

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑